Loading
Life sciences · Journal article
Frontiers in Pain Research · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Obesity and type 2 diabetes mellitus (T2DM) are associated with chronic metabolic dysregulation and microvascular complications, including diabetic peripheral neuropathy (DPN). This case series describes metabolic and patient reported outcomes during ongoing empagliflozin therapy with adjunctive acupuncture treatment. Methods The prospective observational case series included three adult participants with obesity, T2DM, and symptom defined DPN. All participants received empagliflozin 10 mg daily for at least 4 weeks before enrollment and continued treatment while receiving standardized acupuncture twice weekly for 10 weeks. Primary outcomes included body weight, body mass index (BMI), and waist circumference. Secondary outcomes included neuropathic pain intensity assessed using the visual analogue scale (VAS), sleep quality measured by a single-item sleep quality score, and fatigue assessed using the fatigue severity scale were recorded at baseline and week 10. Results All participants completed the intervention without adverse events. The body weight decreased by 4–9 kg, BMI by 1.2–3.5 kg/m 2, and waist circumference by 5–10 cm. VAS reduction range from 2 to 4 points, sleep quality and fatigue scores also improved consistently in all cases. Exploratory outcomes indicated enhanced mobility, reduced nocturnal neuropathic symptoms, and high treatment tolerability. Conclusion Combined therapy with SGLT2 inhibitors and acupuncture was associated with improvements in metabolic, neuropathic, and functional outcomes in obese patients with T2DM, and DPN. These findings suggest that a potential multidimensional therapeutic approach, however, larger controlled studies are required to confirm efficacy.